SBFM Stock Forecast: Sunshine Biopharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Sunshine Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (64): The business earns solid, repeatable profits on what it owns.
Value (7): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SBFM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SBFM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2025 | Aegis Capital | Reiterates | Buy | $7.00 |
| 5 Dec 2024 | Aegis Capital | Reiterates | Buy | — |
| 7 Aug 2023 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
SBFM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SBFM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Sunshine Biopharma, Inc. returned −99.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SBFM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.1×
- Price / book
- 0.0×
- EV / EBITDA
- —
Cheaper than 96% of US stocks
Cheaper than 98% of US stocks
- Revenue growth (YoY)
- 0.3%
- Earnings growth (YoY)
- —
- Gross margin
- 26.2%
- Operating margin
- −16.8%
- Net margin
- −17.5%
Higher than 29% of US stocks
Higher than 29% of US stocks
Higher than 24% of US stocks
Higher than 17% of US stocks
- Return on equity
- −23.4%
- Return on assets
- −11.4%
- Dividend yield
- —
Higher than 31% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sunshine Biopharma, Inc. has a market value of $1.9M.
Revenue in the twelve months to 30 June 2026: $35.3M. The latest quarter shrank 1.6% year on year.
Net income over the same four quarters: −$5.8M, a −16.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.5M.
forward P/E: 0.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Sunshine Biopharma, Inc. employs 50 people — $707K of revenue per employee.
Data provided by Twelve Data
SBFM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SBFM’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Sunshine Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SBFM
How does Ticker Nerd's model rank SBFM?
As at 21 Nov 2026, Sunshine Biopharma, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (64 of 100).
What is the SBFM stock forecast for 2030?
No analyst covering Sunshine Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SBFM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1,120 to $1,120 over the next 12 months.
How has SBFM stock performed over the past year?
Sunshine Biopharma, Inc. returned -99.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sunshine Biopharma, Inc. do?
Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets. The company’s current business spans prescription generic pharmaceuticals and nonprescription over-the-counter products through its operating subsidiaries, alongside a proprietary drug-development pipeline targeting areas with significant unmet medical need.
About Sunshine Biopharma, Inc.
Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets. The company’s current business spans prescription generic pharmaceuticals and nonprescription over-the-counter products through its operating subsidiaries, alongside a proprietary drug-development pipeline targeting areas with significant unmet medical need. Its portfolio includes generic prescription medicines available in Canada, science-based nutritional supplements, and research programs centered on small-molecule, mRNA, and protease-inhibitor candidates. Sunshine Biopharma Inc. serves as a diversified life-sciences platform that combines marketed healthcare products with ongoing therapeutic development, giving it a role in both established pharmaceutical distribution and early-stage drug innovation. Headquartered in Fort Lauderdale, Florida, the company operates primarily in the United States and Canada.
CEO Dr. Steve N. Slilaty Ph.D. · 50 employees · United States · https://sunshinebiopharma.com